hirudin and Cataract

hirudin has been researched along with Cataract* in 2 studies

Other Studies

2 other study(ies) available for hirudin and Cataract

ArticleYear
Inhibitory effect of r-hirudin variant III on streptozotocin-induced diabetic cataracts in rats.
    TheScientificWorldJournal, 2013, Volume: 2013

    The in vivo inhibitory effect of r-hirudin variant III (rHV3) on streptozotocin (STZ)-induced diabetic cataracts in rats was investigated. SD-rats were firstly made diabetic by a single intraperitoneal injection of 2% (W/V) STZ (65 mg/kg). Two weeks later, cataract formation was examined by slit lamp microscope, and the cataracted animals were randomly grouped. The animals in the treated groups received rHV3 drops administration to the eyes with various doses. After 4 weeks treatment, the animals were sacrificed to evaluate the biochemical changes of aldose reductase (AR), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and malondialdehyde (MDA) levels in the eye lens. Meanwhile, the cataract progression was monitored by slit lamp microscope. As a result, rHV3 drops treatment significantly increased the activities of SOD and GSH-Px in the lens in a dose-dependent manner, whereas AR activity and MDA level in the lens were dramatically decreased. Also, the morphological observation further confirmed the inhibition of the development of STZ-induced diabetic cataracts by the rHV3 drops treatment. Thus, our data suggest that rHV3 drops are pharmacologically effective for the protection against STZ-induced diabetic cataracts in rats.

    Topics: Animals; Cataract; Diabetes Mellitus; Diabetes Mellitus, Experimental; Hirudin Therapy; Hirudins; Humans; Male; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Streptozocin; Treatment Outcome

2013
Potential use of hirudin in diabetic cataract: a study of galactose mediated human lens epithelial cells injury.
    Chemico-biological interactions, 2008, May-28, Volume: 173, Issue:2

    Osmotic stress, together with weakened antioxidant defense mechanisms, is attributed to the changes observed in human diabetic cataract. The use of hirudin, an antithrombic agent, in the pathogenesis of human cataracts has not been studied so far. Since the epithelium is the metabolic unit of the lens, the effect of recombinant hirudin variant III (rHV3) on galactose-induced morphological changes and antioxidant status of human lens epithelial line SRA01/04 in culture was evaluated in this study. The human lens epithelial cells (hLECs) were cultured in D/F(12) medium (normal group), D/F(12) medium + 50 mM D-galactose (control group) or D/F(12) medium + 50 mM D-galactose+rHV3 (test group) for 24 or 72 h. The cells were observed under the light, fluorescence and transmission electron microscope for any morphological changes, while the cell viability was assessed by methylthiazol tetrazolium (MTT) assay. The cells in flasks were harvested for the estimation of various antioxidant parameters. Cell morphology, viability, malondialdeyde, glutathione and antioxidant enzymes were significantly altered in the control group as compared with the normal group. Administration of rHV3 confers significant protection against these changes in the human lens epithelial cells. These results demonstrated that rHV3 could effectively protect galactose-induced hLEC injury and suggested that it could have potential use in diabetic cataracts.

    Topics: Catalase; Cataract; Cell Line; Cell Proliferation; Epithelial Cells; Fibrinolytic Agents; Formazans; Galactose; Glutathione; Glutathione Peroxidase; Glutathione Transferase; Hirudins; Humans; Lens, Crystalline; Malondialdehyde; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Recombinant Proteins; Superoxide Dismutase; Tetrazolium Salts

2008